Skip to main content

Advertisement

SpringerLink
Log in

Emerging Invasive Fungal Diseases in Transplantation

  • Transplant and Oncology (MG Ison, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Invasive fungal infections continue to be a major cause of morbidity and mortality in severely immunocompromised transplant patients. Although Candida spp. and Aspergillus spp. represent the majority of identified pathogens, other fungi have become increasingly prevalent among this patient population. Diagnosis and treatment of invasive fungal infections remain a challenge in transplant medicine despite recent major advances. In this review, we will emphasize emerging topics in invasive fungal infections in transplantations that occurred in 2011–2012. The current literature was reviewed to synthesize new trends in epidemiology, recent outbreaks, clinical findings, and advances in diagnostic and therapeutic resources.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:i5–i14.

    Article  PubMed  CAS  Google Scholar 

  2. •• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11. A major cohort study assessing the overall and organ-specific burden of invasive fungal infections among transplants recipients.

    Article  PubMed  Google Scholar 

  3. •• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100. A major prospective study reporting epidemiologic trends of invasive fungal diseases in hematopoietic stem cell transplant recipients.

    Article  PubMed  Google Scholar 

  4. • Lanternier F, Sun H-Y, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54:1–8. A recent literature review in addition to authors’ perspectives on mucormycosis occurring in transplant recipients.

    Article  Google Scholar 

  5. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerging Infect Dis. 2011;17:1855–64.

    Article  PubMed  Google Scholar 

  6. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; Available at: http://www.ncbi.nlm.nih.gov/pubmed/21199154. Accessed 2 March 2011.

  7. Lanternier F, Dannaoui E, Morizot G, et al. A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54:S35–43.

    Article  PubMed  CAS  Google Scholar 

  8. Spellberg B, Kontoyiannis DP, Fredricks D, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22435877. Accessed 22 May 2012.

  9. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715–22.

    Article  PubMed  CAS  Google Scholar 

  10. Zaoutis TE, Webber S, Naftel DC, et al. Invasive fungal infections in pediatric heart transplant recipients: incidence, risk factors, and outcomes. Pediatr Transplant. 2011;15:465–9.

    Article  PubMed  Google Scholar 

  11. Ng B, Dipchand A, Naftel D, et al. Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. Pediatr Transplant. 2011;15:844–8.

    Article  PubMed  Google Scholar 

  12. Däbritz J, Attarbaschi A, Tintelnot K, et al. Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. Mycoses. 2011;54:e785–8.

    Article  PubMed  Google Scholar 

  13. Rammaert B, Lanternier F, Zahar J-R, et al. Healthcare-Associated Mucormycosis. Clin Infect Dis. 2012;54:S44–54.

    Article  PubMed  Google Scholar 

  14. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis. 2010;51:259–65.

    Article  PubMed  CAS  Google Scholar 

  15. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 2002; 17 Suppl 4:36–39.

    Google Scholar 

  16. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S227–33.

    Article  PubMed  Google Scholar 

  17. Phipps LM, Chen SC-A, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation. 2011;92:1327–34.

    Article  PubMed  Google Scholar 

  18. • de Boer MGJ, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13:559–69. A study reviewing 16 recent outbreaks of Pneumocystis jirovecii pneumonia in kidney recipients and describing epidemiological characteristics and clinical risk factors for the disease.

    Article  PubMed  Google Scholar 

  19. • Emergence of Cryptococcus gattii--Pacific Northwest, 2004-2010. Am. J. Transplant. 2011;11:1989–1992. An article that analyzes the occurrence of two major cryptococcal outbreaks in North America.

  20. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia. Canada Emerging Infect Dis. 2011;17:193–9.

    Article  Google Scholar 

  21. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2011;53:1188–95.

    Article  PubMed  CAS  Google Scholar 

  22. Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 2000;343:1163–6.

    Article  PubMed  CAS  Google Scholar 

  23. Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis. 2003;37:1265–9.

    Article  PubMed  Google Scholar 

  24. Mueller NJ, Weisser M, Fehr T, et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis. 2010;12:54–9.

    Article  PubMed  CAS  Google Scholar 

  25. Albano L, Bretagne S, Mamzer-Bruneel M-F, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48:194–202.

    Article  PubMed  Google Scholar 

  26. Baddley JW, Schain DC, Gupte AA, et al. Transmission of Cryptococcus neoformans by Organ Transplantation. Clin Infect Dis. 2011;52:e94–8.

    Article  PubMed  Google Scholar 

  27. Fishman JA, Greenwald MA, Grossi PA. Transmission of Infection With Human Allografts: Essential Considerations in Donor Screening. Clin Infect Dis 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22670038. Accessed 17 July 2012.

  28. Greenwald MA, Kuehnert MJ, Fishman JA. Infectious Disease Transmission during Organ and Tissue Transplantation. Emerging Infect Dis. 2012;18:e1.

    Article  PubMed  Google Scholar 

  29. • Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17. The first prospective study on PET scan in various invasive fungal diseases.

    Article  PubMed  CAS  Google Scholar 

  30. Schmidt S, Tramsen L, Perkhofer S, et al. Characterization of the Cellular Immune Responses to Rhizopus oryzae With Potential Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation. J Infect Dis 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22529315. Accessed 22 May 2012.

  31. Schrödl W, Heydel T, Schwartze VU, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry. J Clin Microbiol. 2012;50:419–27.

    Article  PubMed  Google Scholar 

  32. Coulibaly O, Marinach-Patrice C, Cassagne C, Piarroux R, Mazier D, Ranque S. Pseudallescheria/Scedosporium complex species identification by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry. Med Mycol. 2011;49:621–6.

    PubMed  CAS  Google Scholar 

  33. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49:2151–3.

    Article  PubMed  Google Scholar 

  34. Babady NE, Miranda E, Gilhuley KA. Evaluation of Luminex xTAG fungal analyte-specific reagents for rapid identification of clinically relevant fungi. J Clin Microbiol. 2011;49:3777–82.

    Article  PubMed  Google Scholar 

  35. Steinmann J, Schmidt D, Buer J, Rath P-M. Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequence-based PCR. Med Mycol. 2011;49:475–83.

    PubMed  CAS  Google Scholar 

  36. Lu Q, Gerrits van den Ende AH, Bakkers JM, et al. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J Clin Microbiol. 2011;49:960–7.

    Article  PubMed  CAS  Google Scholar 

  37. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.

    Article  PubMed  Google Scholar 

  38. • Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43. A meta-analysis reporting the performance of BG antigenemia assays for the diagnosis of invasive fungal infections in patients with hematological malignancies.

    Article  PubMed  Google Scholar 

  39. de Boer MGJ, Gelinck LBS, van Zelst BD, et al. β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect. 2011;62:93–100.

    Article  PubMed  Google Scholar 

  40. Costa J-M, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association Between Circulating DNA, Serum (1- > 3)-β-D-Glucan, and Pulmonary Fungal Burden in Pneumocystis Pneumonia. Clin Infect Dis. 2012;55:e5–8.

    Article  PubMed  CAS  Google Scholar 

  41. Hauser PM, Bille J, Lass-Flörl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol. 2011;49:1872–8.

    Article  PubMed  Google Scholar 

  42. Kontoyiannis DP, Lewis RE, Lotholary O, et al. Future directions in mucormycosis research. Clin Infect Dis. 2012;54 Suppl 1:S79–85.

    Article  PubMed  Google Scholar 

  43. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216–24.

    Article  PubMed  CAS  Google Scholar 

  44. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother. 2011;55:3584–7.

    Article  PubMed  CAS  Google Scholar 

  45. Ibrahim AS, Gebremariam T, Luo G, et al. Combination Therapy of Murine Mucormycosis or Aspergillosis with Iron Chelation, Polyenes and Echinocandins. Antimicrob Agents Chemother 2011; Available at: http://www.ncbi.nlm.nih.gov/pubmed/21263057. Accessed 2 March 2011.

  46. Drogari-Apiranthitou M, Mantopoulou F-D, Skiada A, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012;67:1937–40.

    Article  PubMed  CAS  Google Scholar 

  47. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005;40:e35–7.

    Article  PubMed  Google Scholar 

  48. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.

    Article  PubMed  Google Scholar 

  49. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348–55.

    Article  PubMed  Google Scholar 

  50. Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood. 2011;118:5416–9.

    Article  PubMed  CAS  Google Scholar 

  51. Kontoyiannis DP. Deferasirox lacks in vitro activity against Fusarium and Scedosporium species and black molds. Virulence. 2011;2:257–8.

    Article  PubMed  Google Scholar 

  52. Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses. 2011;54 Suppl 3:12–21.

    Article  PubMed  Google Scholar 

  53. Spader TB, Venturini TP, Cavalheiro AS, et al. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses. 2011;54:131–6.

    Article  PubMed  CAS  Google Scholar 

  54. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–50.

    Article  PubMed  CAS  Google Scholar 

  55. Persy B, Vrelust I, Gadisseur A, Ieven M. Phialemonium curvatum fungaemia in an immunocompromised patient: case report. Acta Clin Belg. 2011;66:384–6.

    PubMed  CAS  Google Scholar 

  56. Choi J, Lee Y, Chung H-S, et al. Subcutaneous phaeohyphomycosis caused by Phaeoacremonium species in a kidney transplant patient: the first case in Korea. Korean J Lab Med. 2011;31:201–4.

    Article  PubMed  Google Scholar 

  57. Miossec C, Morio F, Lepoivre T, et al. Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol. 2011;49:2743–7.

    Article  PubMed  Google Scholar 

  58. Pelegrín I, Ayats J, Xiol X, et al. Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review. Transpl Infect Dis. 2011;13:507–14.

    Article  PubMed  Google Scholar 

  59. Rosow L, Jiang JX, Deuel T, et al. Cerebral phaeohyphomycosis caused by Bipolaris spicifera after heart transplantation. Transpl Infect Dis. 2011;13:419–23.

    Article  PubMed  CAS  Google Scholar 

  60. Lief MH, Caplivski D, Bottone EJ, Lerner S, Vidal C, Huprikar S. Exophiala jeanselmei infection in solid organ transplant recipients: report of two cases and review of the literature. Transpl Infect Dis. 2011;13:73–9.

    Article  PubMed  CAS  Google Scholar 

  61. Zhang Y-Q, Xu X-G, Li F-Q, Wei H, Chen H-D, Li Y-H. Co-existence of cutaneous alternariosis and tinea corporis in a renal transplant recipient. Med Mycol. 2011;49:435–8.

    Article  PubMed  Google Scholar 

  62. Rammaert B, Aguilar C, Bougnoux M-E, et al. Success of posaconazole therapy in a heart transplanted patient with Alternaria infectoria cutaneous infection. Med. Mycol. 2011; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22142219. Accessed 2 April 2012.

  63. Vignon M, Michonneau D, Baixench M-T, et al. Disseminated Scopulariopsis brevicaulis infection in an allogeneic stem cell recipient. Bone Marrow Transplant. 2011;46:1276–7.

    Article  PubMed  CAS  Google Scholar 

  64. Ryan LJ, Ferrieri P, Powell Jr RD, Paddock CD, Zaki SR, Pambuccian SE. Fatal Cokeromyces recurvatus pneumonia: report of a case highlighting the potential for histopathologic misdiagnosis as coccidioides. Int J Surg Pathol. 2011;19:373–6.

    Article  PubMed  Google Scholar 

  65. Spellberg B, Ibrahim A, Roilides E, et al. Combination Therapy for Mucormycosis: Why, What, and How? Clin Infect Dis. 2012;54:S73–8.

    Article  PubMed  CAS  Google Scholar 

  66. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125:S25–38.

    Article  PubMed  CAS  Google Scholar 

  67. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

P. Parize has received grant support from patient association “Vaincre la mucoviscidose” and travel and accommodation support from Sanofi; B. Rammaert has received honoraria from Gilead and travel and accommodation support from MSD; O. Lortholary is a member of the MSD board, is a consultant for Astellas and Gilead Sciences and received grants speaker's fees from MSD, Astellas, Gilead Sciences and Pfizer.

Author information

Authors and Affiliations

  1. Université Paris-Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, APHP, Centre d’Infectiologie Necker-Pasteur, Institut Hospitalo-Universitaire Imagine, 149, rue de Sèvres, 75743, Paris Cedex 15, France

    Perrine Parize, Blandine Rammaert & Olivier Lortholary

  2. Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS URA3012, Paris, France

    Olivier Lortholary

Authors
  1. Perrine Parize
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blandine Rammaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Lortholary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Lortholary.

Additional information

Perrine Parize, Blandine Rammaert are contributed equally to the present article

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parize, P., Rammaert, B. & Lortholary, O. Emerging Invasive Fungal Diseases in Transplantation. Curr Infect Dis Rep 14, 668–675 (2012). https://doi.org/10.1007/s11908-012-0296-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-012-0296-y

Keywords

Search

Navigation